Your browser doesn't support javascript.
loading
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
Anderlini, Paolo; Saliba, Rima M; Ledesma, Celina; Plair, Tamera; Alousi, Amin M; Hosing, Chitra M; Khouri, Issa F; Nieto, Yago; Popat, Uday R; Shpall, Elizabeth J; Fanale, Michelle A; Hagemeister, Frederick B; Oki, Yasuhiro; Neelapu, Saatva; Romaguera, Jorge E; Younes, Anas; Champlin, Richard E.
Afiliação
  • Anderlini P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas. Electronic address: panderli@mdanderson.org.
  • Saliba RM; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Ledesma C; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Plair T; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Alousi AM; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Hosing CM; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Khouri IF; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Nieto Y; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Popat UR; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Shpall EJ; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Fanale MA; Department of Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Hagemeister FB; Department of Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Oki Y; Department of Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Neelapu S; Department of Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Romaguera JE; Department of Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
  • Younes A; Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Champlin RE; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Biol Blood Marrow Transplant ; 22(7): 1333-1337, 2016 07.
Article em En | MEDLINE | ID: mdl-27064056
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vidarabina / Doença de Hodgkin / Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Desoxicitidina / Melfalan Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vidarabina / Doença de Hodgkin / Transplante de Células-Tronco Hematopoéticas / Condicionamento Pré-Transplante / Desoxicitidina / Melfalan Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article